Literature DB >> 33637765

Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.

Akiko Shimamura1,2, R Coleman Lindsley3, Alyssa L Kennedy1,2, Kasiani C Myers4,5, James Bowman1,2,6, Christopher J Gibson7, Nicholas D Camarda8, Elissa Furutani1,2, Gwen M Muscato9, Robert H Klein8,10, Kaitlyn Ballotti9, Shanshan Liu11, Chad E Harris9, Ashley Galvin9, Maggie Malsch9, David Dale12, John M Gansner13, Taizo A Nakano14, Alison Bertuch15, Adrianna Vlachos16,17, Jeffrey M Lipton16,17, Paul Castillo18, James Connelly19, Jane Churpek20, John R Edwards21, Nobuko Hijiya22, Richard H Ho19, Inga Hofmann23, James N Huang24,25, Siobán Keel26, Adam Lamble27, Bonnie W Lau28,29, Maxim Norkin30, Elliot Stieglitz24,31, Wendy Stock32, Kelly Walkovich33, Steffen Boettcher34, Christian Brendel1,2,35, Mark D Fleming36, Stella M Davies4,5, Edie A Weller1,11, Christopher Bahl1,2,6, Scott L Carter10,37.   

Abstract

To understand the mechanisms that mediate germline genetic leukemia predisposition, we studied the inherited ribosomopathy Shwachman-Diamond syndrome (SDS), a bone marrow failure disorder with high risk of myeloid malignancies at an early age. To define the mechanistic basis of clonal hematopoiesis in SDS, we investigate somatic mutations acquired by patients with SDS followed longitudinally. Here we report that multiple independent somatic hematopoietic clones arise early in life, most commonly harboring heterozygous mutations in EIF6 or TP53. We show that germline SBDS deficiency establishes a fitness constraint that drives selection of somatic clones via two distinct mechanisms with different clinical consequences. EIF6 inactivation mediates a compensatory pathway with limited leukemic potential by ameliorating the underlying SDS ribosome defect and enhancing clone fitness. TP53 mutations define a maladaptive pathway with enhanced leukemic potential by inactivating tumor suppressor checkpoints without correcting the ribosome defect. Subsequent development of leukemia was associated with acquisition of biallelic TP53 alterations. These results mechanistically link leukemia predisposition to germline genetic constraints on cellular fitness, and provide a rational framework for clinical surveillance strategies.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33637765      PMCID: PMC7910481          DOI: 10.1038/s41467-021-21588-4

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  59 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Alternate states of proteins revealed by detailed energy landscape mapping.

Authors:  Michael D Tyka; Daniel A Keedy; Ingemar André; Frank Dimaio; Yifan Song; David C Richardson; Jane S Richardson; David Baker
Journal:  J Mol Biol       Date:  2010-11-10       Impact factor: 5.469

3.  Structure prediction for CASP8 with all-atom refinement using Rosetta.

Authors:  Srivatsan Raman; Robert Vernon; James Thompson; Michael Tyka; Ruslan Sadreyev; Jimin Pei; David Kim; Elizabeth Kellogg; Frank DiMaio; Oliver Lange; Lisa Kinch; Will Sheffler; Bong-Hyun Kim; Rhiju Das; Nick V Grishin; David Baker
Journal:  Proteins       Date:  2009

4.  The Catalogue of Somatic Mutations in Cancer (COSMIC).

Authors:  S A Forbes; G Bhamra; S Bamford; E Dawson; C Kok; J Clements; A Menzies; J W Teague; P A Futreal; M R Stratton
Journal:  Curr Protoc Hum Genet       Date:  2008-04

5.  The Shwachman-Diamond SBDS protein localizes to the nucleolus.

Authors:  Karyn M Austin; Rebecca J Leary; Akiko Shimamura
Journal:  Blood       Date:  2005-04-28       Impact factor: 22.113

6.  A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.

Authors:  Steffen Boettcher; Peter G Miller; Rohan Sharma; Marie McConkey; Matthew Leventhal; Andrei V Krivtsov; Andrew O Giacomelli; Waihay Wong; Jesi Kim; Sherry Chao; Kari J Kurppa; Xiaoping Yang; Kirsten Milenkowic; Federica Piccioni; David E Root; Frank G Rücker; Yael Flamand; Donna Neuberg; R Coleman Lindsley; Pasi A Jänne; William C Hahn; Tyler Jacks; Hartmut Döhner; Scott A Armstrong; Benjamin L Ebert
Journal:  Science       Date:  2019-08-09       Impact factor: 47.728

7.  Deficiency of Sbds in the mouse pancreas leads to features of Shwachman-Diamond syndrome, with loss of zymogen granules.

Authors:  Marina E Tourlakis; Jian Zhong; Rikesh Gandhi; Siyi Zhang; Lingling Chen; Peter R Durie; Johanna M Rommens
Journal:  Gastroenterology       Date:  2012-04-14       Impact factor: 22.682

8.  Shwachman-Diamond syndrome marrow cells show abnormally increased apoptosis mediated through the Fas pathway.

Authors:  Y Dror; M H Freedman
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

Review 9.  Molecular basis of the human ribosomopathy Shwachman-Diamond syndrome.

Authors:  Alan J Warren
Journal:  Adv Biol Regul       Date:  2017-09-06

10.  Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis.

Authors:  Fernando G Osorio; Axel Rosendahl Huber; Rurika Oka; Mark Verheul; Sachin H Patel; Karlijn Hasaart; Lisanne de la Fonteijne; Ignacio Varela; Fernando D Camargo; Ruben van Boxtel
Journal:  Cell Rep       Date:  2018-11-27       Impact factor: 9.423

View more
  29 in total

1.  Diagnosis and therapeutic decision-making for the neutropenic patient.

Authors:  James A Connelly; Kelly Walkovich
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Mechanisms of somatic transformation in inherited bone marrow failure syndromes.

Authors:  Haruna Batzorig Choijilsuren; Yeji Park; Moonjung Jung
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 3.  CHIP: is clonal hematopoiesis a surrogate for aging and other disease?

Authors:  Lukasz P Gondek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 4.  The clinical and laboratory evaluation of patients with suspected hypocellular marrow failure.

Authors:  Siobán Keel; Amy Geddis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

5.  Impaired myelopoiesis in congenital neutropenia: insights into clonal and malignant hematopoiesis.

Authors:  Julia T Warren; Daniel C Link
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 6.  When does a PNH clone have clinical significance?

Authors:  Daria V Babushok
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

7.  The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis.

Authors:  Yash B Shah; Salvatore F Priore; Yimei Li; Chi N Tang; Peter Nicholas; Peter Kurre; Timothy S Olson; Daria V Babushok
Journal:  Blood Adv       Date:  2021-08-24

8.  Somatic genetic rescue of a germline ribosome assembly defect.

Authors:  Shengjiang Tan; Laëtitia Kermasson; Christine Hilcenko; Vasileios Kargas; David Traynor; Ahmed Z Boukerrou; Norberto Escudero-Urquijo; Alexandre Faille; Alexis Bertrand; Maxim Rossmann; Beatriz Goyenechea; Li Jin; Jonathan Moreil; Olivier Alibeu; Blandine Beaupain; Christine Bôle-Feysot; Stefano Fumagalli; Sophie Kaltenbach; Jean-Alain Martignoles; Cécile Masson; Patrick Nitschké; Mélanie Parisot; Aurore Pouliet; Isabelle Radford-Weiss; Frédéric Tores; Jean-Pierre de Villartay; Mohammed Zarhrate; Ai Ling Koh; Kong Boo Phua; Bruno Reversade; Peter J Bond; Christine Bellanné-Chantelot; Isabelle Callebaut; François Delhommeau; Jean Donadieu; Alan J Warren; Patrick Revy
Journal:  Nat Commun       Date:  2021-08-19       Impact factor: 17.694

Review 9.  Somatic mosaicism in inherited bone marrow failure syndromes.

Authors:  Fernanda Gutierrez-Rodrigues; Sushree S Sahoo; Marcin W Wlodarski; Neal S Young
Journal:  Best Pract Res Clin Haematol       Date:  2021-06-27       Impact factor: 3.670

Review 10.  Clonal hematopoiesis and risk for hematologic malignancy.

Authors:  Julia T Warren; Daniel C Link
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.